Targeting Mitosis to Reprogram the Tumor Microenvironment: Combination Strategies for Cancer Immunotherapy
Cancer Biome and Targeted Therapy · 14.11.2026 · 127-171
DOI: 10.66505/cbtt.v1i4.62 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biome and Targeted Therapy, online erschienen am 14.11.2026. Verfasst von Fazhi Yu und 3 weiteren Autor:innen. Die Arbeit nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Anhui Province, University of Science and Technology of China, National Science and Technology Major Project.
Abstract (Originalsprache)
Dysregulated mitosis is a therapeutic vulnerability in cancer, but the consequences of mitotic targeting extend beyond tumor-cell death. Chromosome missegregation, micronucleus formation, and chromatin-bridge exposure can activate cytosolic DNA sensing and alter inflammatory signaling, immune recognition, and stromal interactions within the tumor microenvironment (TME). These responses are not uniformly antitumor. Acute mitotic perturbation may enhance innate immune activation and tumor-cell susceptibility to immune elimination, whereas persistent chromosomal instability can promote inflammatory adaptation, myeloid immunosuppression, and immune escape. This distinction has important implications for combining antimitotic agents with immunotherapy. Here, we examine the molecular mechanisms linking mitotic disruption to TME remodeling, with particular emphasis on signaling through cyclic GMP–AMP synthase (cGAS) and stimulator of interferon genes (STING), immune checkpoint regulation, myeloid-cell responses, and stromal reorganization. We evaluate combination strategies involving immune checkpoint blockade, innate immune modulation, myeloid targeting, radiotherapy, and cell-death-enhancing interventions. Although preclinical studies provide mechanistic support for several approaches, clinical evidence remains uneven, and the immune consequences of individual antimitotic agents are difficult to predict across tumor types. We propose a testable framework integrating baseline chromosomal instability, p53 status, innate immune competence, and early treatment-induced biomarkers to guide therapeutic selection and scheduling. Translating this framework into clinical practice will require prospective validation, clearer separation of drug-specific effects from general mitotic stress responses, and evidence that immune remodeling improves patient outcomes.
Förderung
- Natural Science Foundation of Anhui Province
- University of Science and Technology of China
- National Science and Technology Major Project
Zitieren
APA
Yu, F., Ji, S., Guo, J., & Yang, Z. (2026). Targeting Mitosis to Reprogram the Tumor Microenvironment: Combination Strategies for Cancer Immunotherapy. Cancer Biome and Targeted Therapy, 127-171. https://doi.org/10.66505/cbtt.v1i4.62
Vancouver
Yu F, Ji S, Guo J, Yang Z. Targeting Mitosis to Reprogram the Tumor Microenvironment: Combination Strategies for Cancer Immunotherapy. Cancer Biome and Targeted Therapy. 2026:127-171. doi:10.66505/cbtt.v1i4.62
BibTeX
@article{Yu2026,
author = {Yu, Fazhi and Ji, Shuaishuai and Guo, Jing and Yang, Zhenye},
title = {Targeting Mitosis to Reprogram the Tumor Microenvironment: Combination Strategies for Cancer Immunotherapy},
journal = {Cancer Biome and Targeted Therapy},
year = {2026},
pages = {127--171},
doi = {10.66505/cbtt.v1i4.62}
}
EUVIMED